A step towards treating KRAS-mutant NSCLC
Mené sur 44 patients atteints d'un cancer du poumon non à petites cellules avec mutations du gène KRAS, cet essai de phase II évalue, du point de vue de la survie globale, l'ajout de selumetinib au docétaxel
During the past few years, oncologists have witnessed the reclassification of non-small-cell lung cancer (NSCLC) as not one disease, but several molecularly defined subsets of disease. The largest subset harbours an activating KRAS mutation and includes about 25% of all patients with lung cancer, mainly adenocarcinoma. Other less common genetically defined subsets of NSCLC, including those with EGFR or ALK activating mutations, show high sensitivity to tyrosine-kinase inhibitors such that patients frequently have sustained clinical responses to therapy. By contrast, KRAS has remained an elusive target for cancer therapy.4 Up to now, no successful targeted therapy has been developed for RAS-mutant lung cancer, and few compounds have been assessed by clinical trial...
The Lancet Oncology , commentaire, 2011